Susquehanna Fundamental Investments’s Xeris Biopharma Holdings XERS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,087	Closed	-$139K	–	708
2025 Q3	$139K	Hold	17,087	–	–	0.01%	528
2025 Q2	$79.8K	Hold	17,087	–	–	﹤0.01%	701
2025 Q1	$93.8K	Sell	17,087 -2,625	-13%	-$10.6K	﹤0.01%	1030
2024 Q4	$66.8K	Buy	+19,712	New	+$63.4K	﹤0.01%	1052
2022 Q1	$170K	Sell	66,540 -120,117	-64%	-$293K	﹤0.01%	1393
2021 Q4	$547K	Sell	186,657 -87,816	-32%	-$190K	0.01%	881
2021 Q3	$672K	Buy	274,473 +130,834	+91%	+$380K	0.01%	1065
2021 Q2	$585K	Buy	+143,639	New	+$548K	0.01%	1093
2021 Q1	–	Sell	-14,132	Closed	-$70K	–	1629
2020 Q4	$70K	Buy	+14,132	New	+$70.7K	﹤0.01%	1442

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna Fundamental Investments's XERS Position: Q4 2025 in Review

Susquehanna Fundamental Investments sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 17,087 shares — an estimated $139K sold.

Susquehanna Fundamental Investments first reported a position in XERS in Q4 2020 and held it in 9 quarters. The position peaked at $672K in Q3 2021. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

Susquehanna Fundamental Investments reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 17,087 Xeris Biopharma Holdings shares in Q4 2025, an estimated $139K.
Susquehanna Fundamental Investments first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 9 quarters.
Susquehanna Fundamental Investments's Xeris Biopharma Holdings position peaked at $672K in Q3 2021.
225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2025, filed 17 Feb 2026.